> Details

Valmori, Danila; Souleimanian, Naira E.; Tosello, Valeria; Bhardwaj, Nina; Adams, Sylvia; O'Neill, David; Pavlick, Anna; Escalon, Juliet B.; Cruz, Crystal M.; Angiulli, Angelica; Angiulli, Francesca; Mears, Gregory; Vogel, Susan M.; Pan, Linda; Jungbluth, Achim A.; Hoffmann, Eric W.; Venhaus, Ralph; Ritter, Gerd; Old, Lloyd J.; Ayyoub, Maha

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
  • Contributor: Valmori, Danila; Souleimanian, Naira E.; Tosello, Valeria; Bhardwaj, Nina; Adams, Sylvia; O'Neill, David; Pavlick, Anna; Escalon, Juliet B.; Cruz, Crystal M.; Angiulli, Angelica; Angiulli, Francesca; Mears, Gregory; Vogel, Susan M.; Pan, Linda; Jungbluth, Achim A.; Hoffmann, Eric W.; Venhaus, Ralph; Ritter, Gerd; Old, Lloyd J.; Ayyoub, Maha
  • imprint: Proceedings of the National Academy of Sciences, 2007
  • Published in: Proceedings of the National Academy of Sciences
  • Language: English
  • DOI: 10.1073/pnas.0703395104
  • ISSN: 0027-8424; 1091-6490
  • Origination:
  • Footnote:
  • Description: <jats:p> The use of recombinant tumor antigen proteins is a realistic approach for the development of generic cancer vaccines, but the potential of this type of vaccines to induce specific CD8 <jats:sup>+</jats:sup> T cell responses, through <jats:italic>in vivo</jats:italic> cross-priming, has remained unclear. In this article, we report that repeated vaccination of cancer patients with recombinant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helper type 1 (Th1)-type immunity, resulted in the early induction of specific integrated CD4 <jats:sup>+</jats:sup> Th cells and antibody responses in most vaccinated patients, followed by the development of later CD8 <jats:sup>+</jats:sup> T cell responses in a fraction of them. The correlation between antibody and T cell responses, together with the ability of vaccine-induced antibodies to promote <jats:italic>in vitro</jats:italic> cross-presentation of NY-ESO-1 by dendritic cells to vaccine-induced CD8 <jats:sup>+</jats:sup> T cells, indicated that elicitation of NY-ESO-1-specific CD8 <jats:sup>+</jats:sup> T cell responses by cross-priming <jats:italic>in vivo</jats:italic> was associated with the induction of adequate levels of specific antibodies. Together, our data provide clear evidence of <jats:italic>in vivo</jats:italic> cross-priming of specific cytotoxic T lymphocytes by a recombinant tumor antigen vaccine, underline the importance of specific antibody induction for the cross-priming to occur, and support the use of this type of formulation for the further development of efficient cancer vaccines. </jats:p>
  • Access State: Open Access